Y. Duncan-Roberts

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

E. García‐Iglesias, I. García-García, I. Bello-Rivero, 2012, BMC Pharmacology and Toxicology.

Phase II randomized controlled trial to evaluate the efficacy and safety of HeberFERON versus Heberon alpha R in symptomatic or asymptomatic patients infected with the SARS-CoV-2 (Study ESPERANZA/HOPE).

F. Hernández-Bernal, G. Guillén-Nieto, Y. Duncan-Roberts, 2020 .

Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON

C. Valenzuela-Silva, M. rodríguez-garCía, E. García‐Iglesias, 2022, medRxiv.

Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care

I. Bello-Rivero, Y. Duncan-Roberts, M. Fernández-Martori, 2018 .

HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.

Vladimir Besada-Pérez, I. Bello-Rivero, Y. García-Vega, 2018, Seminars in oncology.

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

O. Reyes-Acosta, I. Bello-Rivero, Y. García-Vega, 2021, medRxiv.

A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial

E. Fish, M. Béquet-Romero, F. Hernández-Bernal, 2021 .

Evaluation of the Effect and Safety of HeberFERON vs Heberon Alpha in Patients Infected with Corona Virus SARS-CoV-2 (Study ESPERANZA/HOPE): Study Protocol for a Randomized Controlled Trial.

F. Hernández-Bernal, G. Guillén-Nieto, Y. Duncan-Roberts, 2020 .

Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding

M. García-Sánchez, I. Bello-Rivero, Y. Duncan-Roberts, 2021, Journal of Biomedical Research & Environmental Sciences.